StockData

Moleculin Biotech vs Pyxis Oncology

MBRX and PYXS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MBRX and PYXS compare

Moleculin Biotech and Pyxis Oncology are about the same size, with market caps of $133M and $120M.

Pyxis Oncology scores higher on the StockData Score (5 against 4 for Moleculin Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMBRXPYXS
Size and price
Market cap$133M$120M
Share price$6.83$1.44
Change, 1 year−96.9%−67.0%
Change, 5 years−100.0%−88.8%
Beta (5Y)−1.103.15
Employees150K56
StockData Score
Total score45 (better)
Valuation score00
Growth score00
Performance score00
Health score45 (better)
Dividend score00
Valuation
P/B11.5×10.5× (better)
Profitability
Return on equity−524%−179% (better)
Financial health
Debt / equity0.000.00
Current ratio0.941.34 (better)
Altman Z-score−11.19 (better)−16.21
Piotroski F-score3 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions0.05%40.9%
Held by insiders20.2%20.4%
Insider net buying, 12 months–−$107K
Short interest, % of float0.35%6.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.